Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg).

Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks. Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences Ltd, Baddi, Himachal Pradesh.

Verapamil Hydrochloride Extended-Release Tablets had annual sales of USD 24.5 mn in the United States (IQVIA MAT Sept-2025).

The group now has 428 approvals and has so far filed 487* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 927.50 as compared to the previous close of Rs. 926.60. The total number of shares traded during the day was 7247 in over 622 trades.

The stock hit an intraday high of Rs. 935.00 and intraday low of 922.80. The net turnover during the day was Rs. 6748626.00.

(*As on 30-Sept-25)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA FinalApproval VerapamilHydrochloride ExtendedReleaseTablets